BofA’s Hartnett says concentrated U.S. stock returns are likely to persist
PURCHASE, N.Y. - Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage biopharmaceutical company focused on neurodegenerative disorders with a current market capitalization of $30.35 million, is slated to present its Phase 2 study results of Alzheimer’s drug zervimesine at the upcoming AD/PD™ 2025 Conference in Vienna, Austria, on April 1-5. According to InvestingPro data, the company maintains a healthy balance sheet with more cash than debt and a current ratio of 2.65x, though it’s currently trading below its Fair Value. Dr. Mary Hamby, the company’s VP of research, will discuss the impact of zervimesine on key proteins linked to Alzheimer’s progression.
The SHINE study examined blood biomarkers including neurofilament light chain, glial fibrillary acidic protein, amyloid beta, and tau species in patients with mild-to-moderate Alzheimer’s disease. Dr. Hamby’s presentation will highlight changes in these biomarkers among participants treated with zervimesine compared to a placebo group. The findings aim to provide a more comprehensive view of the drug’s effects when combined with previously observed cognitive and functional benefits.
Cognition Therapeutics’ research at the conference will also feature poster presentations on the identification of cerebrospinal fluid proteins correlating with cognitive outcomes and the modulation effects of zervimesine on Alzheimer’s disease.
Zervimesine, the lead candidate of Cognition Therapeutics, operates through interaction with the sigma-2 receptor, a novel approach compared to existing treatments for degenerative diseases. The company is currently investigating its efficacy in dementia with Lewy bodies and Alzheimer’s disease, including an ongoing early-stage Alzheimer’s study.
The information presented in this article is based on a press release statement from Cognition Therapeutics, Inc. The company’s forward-looking statements regarding the potential benefits of zervimesine and anticipated outcomes of clinical trials are subject to risks and uncertainties that may cause actual results to differ. These statements do not guarantee future performance and are based on current expectations, which involve a range of known and unknown risks. For comprehensive analysis and additional insights, investors can access detailed financial metrics and 8 more exclusive ProTips through InvestingPro’s detailed research report, part of its coverage of over 1,400 US stocks.
In other recent news, Cognition Therapeutics reported a net loss of $34 million for the fiscal year 2024, maintaining the same per-share loss as the previous year. The company is focusing on its Alzheimer’s and Dementia with Lewy Bodies (DLB) programs, redirecting resources from other projects, including halting its Phase 2 study for dry acute macular degeneration. This strategic shift is intended to extend its cash runway into late 2025. Cognition Therapeutics has raised $12.8 million through an at-the-market facility, which is expected to support operations into the fourth quarter of 2025.
Additionally, H.C. Wainwright adjusted its price target for Cognition Therapeutics to $5 while maintaining a Buy rating, reflecting an extended timeline for the company’s lead candidate, zervimesine, to reach the market. In contrast, Brookline Capital Markets raised its price target to $7, also maintaining a Buy rating, citing the company’s fiscal year 2024 results and clinical advancements as positive indicators. Cognition Therapeutics’ research and development expenses for the year were $8.2 million, below the $10.7 million estimate, while grant income fell short of expectations.
The company is preparing for end-of-Phase 2 meetings with the FDA to discuss Phase 3 protocols for Alzheimer’s and DLB, with feedback anticipated by mid-2025. Cognition Therapeutics is actively seeking partnerships and out-licensing opportunities to support its clinical development efforts. The firm remains optimistic about regaining NASDAQ compliance by September 2025, amidst ongoing financial challenges and strategic realignments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.